Atypical antipsychotics are the mainstay of therapy in the treatment of schizophrenia, due to their effective management of both positive and negative symptoms. However, relapses resulting from partial compliance with therapy can limit the clinical success of these agents. Treatment options in schizophrenia have been further limited by a lack of long-acting atypical antipsychotics. Researchers at the 6th European Congress of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) [Barcelona, Spain; November 2003] presented data that showed the potential for improved outcomes and cost savings following treatment with the first long-acting injectable atypical antipsychotic risperidone [Risperdal Consta] in patients with schizophrenia, schizoaffective disorder or other psychotic disorders.1,2